4//SEC Filing
McCracken Joseph S 4
Accession 0001250853-21-000085
CIK 0001561743other
Filed
Aug 29, 8:00 PM ET
Accepted
Aug 30, 2:55 PM ET
Size
15.3 KB
Accession
0001250853-21-000085
Insider Transaction Report
Form 4
McCracken Joseph S
Director
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2021-08-27−41,890→ 0 totalExercise: $9.65Exp: 2028-04-19→ Common Stock (41,890 underlying) - Disposition to Issuer
Stock Option (right to buy)
2021-08-27$4.81/sh−48,500$233,285→ 0 totalExercise: $4.44Exp: 2031-01-19→ Common Stock (48,500 underlying) - Disposition to Issuer
Stock Option (right to buy)
2021-08-27−10,000→ 0 totalExercise: $11.00Exp: 2028-06-21→ Common Stock (10,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2021-08-27−48,500→ 0 totalExercise: $9.91Exp: 2029-01-31→ Common Stock (48,500 underlying) - Disposition to Issuer
Stock Option (right to buy)
2021-08-27−48,500→ 0 totalExercise: $9.84Exp: 2030-01-16→ Common Stock (48,500 underlying)
Footnotes (5)
- [F1]This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the agreement and plan of merger, dated as of June 15, 2021, by and among the Elanco Animal Health Incorporated, Knight Merger Sub, Inc., and Kindred Biosciences, Inc. (the "Merger Agreement") in exchange for no consideration.
- [F2]This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the Merger Agreement in exchange for no consideration.
- [F3]This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the Merger Agreement in exchange for no consideration.
- [F4]This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the Merger Agreement in exchange for no consideration.
- [F5]This option provided for vesting in four equal quarterly installments from the option grant date. Pursuant to the Merger Agreement, the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $233,285.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.
Documents
Issuer
Kindred Biosciences, Inc.
CIK 0001561743
Entity typeother
Related Parties
1- filerCIK 0001632454
Filing Metadata
- Form type
- 4
- Filed
- Aug 29, 8:00 PM ET
- Accepted
- Aug 30, 2:55 PM ET
- Size
- 15.3 KB